

# Cumulative Index 1991

## Volume 14

---

<i>March</i>	<b>PERVASIVE DEVELOPMENTAL DISORDERS</b> , pages 1-222
<i>June</i>	<b>ALZHEIMER'S DISEASE</b> , pages 223-487
<i>September</i>	<b>MULTIPLE PERSONALITY DISORDER</b> , pages 489-791
<i>December</i>	<b>ELECTROCONVULSIVE THERAPY</b> , pages 793-1035

---

*Note:* Page numbers of article titles are in **boldface** type.

- Abreactions, fractionated, MPD treatment and, 672-673
- Acetylcholine, in Alzheimer's disease, 422-423
- Acetylcholine precursors, for cognitive impairment in Alzheimer's disease, 467
- Acetylcholinesterase, in Alzheimer's disease, 290
- Acetylcholinesterase inhibitors, for cognitive impairment in Alzheimer's disease, 464-467
- Acetyl-L-carnitine, for cognitive impairment in Alzheimer's disease, 470
- Activities of daily living scales, in Alzheimer's disease, 318-320
- Ad hoc multiple personality disorder, 625
- Adolescents. *See also Children.*  
dissociative disorders in, **519-529**
- Affect, autism and, 25-27, 130
- Affective symptoms, in MPD, 601-602, 730-731
- Age, parental, and Alzheimer's disease risk, 259  
seizure threshold and, in ECT, 813-815
- Age regression, spontaneous, MPD and, 581-582
- Aging, normal, senile dementia of  
Alzheimer type versus, 398-400
- Agitation, in Alzheimer's disease, 342-344
- Alter personalities. *See also Alternative identities; Multiple personality disorder (MPD).*  
attributes and presence of, 593-594  
automatic thoughts of, 663-665  
blending of, 673-674  
characteristics of, 610-611  
like-clusters of, MPD treatment and, 672  
mapping of, 670-671  
physiological differences in, 491-494  
switching between, 598-600  
eye roll with, 585-586
- Alternative identities. *See also Alter personalities.*  
embodied, **769-785**  
Alzheimer's disease, **223-487**  
assessment of, **309-322**  
behavioral problems in, **341-349**. *See also Behavioral problems, in Alzheimer's disease.*  
causes of death and, 257-258  
CERAD and, 225-228  
clinical diagnosis of, **223-234**  
problem of, 251-252  
clinical diagnostic criteria of, 223-225  
clinical genetic studies of, **267-284**  
case-control studies, 268  
family history studies of cumulative risk, 269-275  
future prospects for, 282-284  
genetic linkage studies, 276-282  
pedigree studies, 276  
twin studies, 268-269  
cognitive impairment in, treatment of, **461-474**  
course of, **223-234**  
definition of, 251  
depression in, **327-336**. *See also Depression, in Alzheimer's disease.*

- Alzheimer's disease (*Continued*)  
 diagnosis of, accuracy of, 253  
 differential diagnosis of, 229-230, 237-246  
 Down's syndrome and, 259  
 epidemiology of, 228, 251-261  
 familial aggregation of, 258-259  
 family counseling and legal issues in, 385-394  
 histologic diagnosis of, problem of, 252-253  
 incidence of, 254  
 lifetime cumulative risk of, 254-255  
 longitudinal course of, 233  
 magnitude of, 253-261  
 and mortality, 256  
 neurochemical and receptor changes in, 290-291  
 neuroimaging in, 443-455  
 neurotransmitter systems and, 288-300, 409-410  
 neuropeptides and, 421-434  
 noncognitive abnormalities in, 341-349  
 normal aging versus, 398-400  
 parental age and, 259  
 Parkinson's disease and, 259  
 pathology of, 397-414  
   amyloid and diffuse plaques in, 400-406  
   extraneural manifestations of, 410-411  
   granulovacuolar neuronal degeneration in, 409  
   Hirano bodies in, 409  
   historical aspects of, 397-398  
   hypotheses of, 411-414  
   neurofibrillary tangles in, 406-409  
   neurotransmitter systems in, 409-410  
   vascular disease and, 411  
 pharmacologic models of, 287-303  
 prevalence of, 254  
 prognostic factors in, 257  
 risk factors for, 258-261  
 staging of, 315-318  
 and survival, 256  
 thyroid disease and, 259, 261  
 variations in, by persons, place, and time, 255  
 Alzheimer's Disease Assessment Scale, 313  
   noncognitive subscale of, 322  
 Amino acid neurotransmitters, in Alzheimer's disease, 432-433  
 4-Aminopyridine, for cognitive impairment in Alzheimer's disease, 467  
 Amnesia symptoms, in mental status examination for assessment of MPD and dissociative disorders, 572-580  
 Amyloid, and diffuse plaques, in Alzheimer's disease, 400-406, 472  
 Anesthesia/analgesia, effect on seizure threshold, in ECT, 815-816  
   voluntary, MPD and, 583-584  
 Aneurysm, aortic, ECT and, 877  
 Animal models of Alzheimer's disease, 293-295  
 Anticonvulsants, and seizure threshold, in ECT, 817-819  
 Antidepressants, in MPD, 733-734  
   tricyclic, and cholinergic function, 299  
   and seizure threshold, in ECT, 819  
 Antihypertensives, ECT and, 874  
 Antipsychiatry movement, impact of, on revival of ECT in United States, 793-800  
 Antipsychotics, and cholinergic function, 299-300  
 Antisocial personality disorder, comorbidity of MPD and, 559-560  
 Anxiety, MPD and, 590-591, 732-736  
 Aortic aneurysm, ECT and, 877  
 Appearance, MPD and, 570  
 Asperger's syndrome, 81-91  
   assessment of, 88  
   associated handicaps with, 86-87  
   diagnostic features of, 82-83  
   differential diagnosis of, 83-86  
   etiology of, 87-88  
   outcome of, 90-91  
   phenotype and, 129  
   treatment of, 88-90  
 Assessment scales, for Alzheimer's disease, 309-322  
 Attachment, autism and, 27  
 Attention, Alzheimer's disease and, scopolamine and, 295, 297  
 Atypical development, 55-56  
 Atypical multiple personality disorder, 623  
 "Atypical ontogeny," 54-55  
 order  
 Autism, 1-14. *See also* *Autistic disorder*.  
   affect and, 25-27, 130  
   Asperger's syndrome versus, 83-85  
   clinical description of, 1-2  
   developmentally ordering symptoms of, 53-54  
   diagnosis of, *décalage* as organizing construct in, 60-62  
   future trends in, 76-77  
   interpretation of results of measures in, 75-76  
   issues in conceptualization of, 70-73  
   methods and measures of behavior in, 69-78  
   methods of information collection for, 73-75  
   false-negative diagnosis of, DSM scoring procedure and, 62  
   fragile X and, 131-133  
   genetic influences in, 125-137  
   interactive studies of, 27  
   language impairment and, 11, 23-25, 102-104  
   normal development versus, 8-10

- psychiatric treatment of, functional neuroanatomy of, 118-122  
research strategies applied to, 3-5  
social deviance in, 19-30  
theory of, 2-8, 10-13  
theory of mind in, 33-48  
tuberous sclerosis and, 133-135  
understanding of mental states in, 35-36
- Autistic disorder. *See also Autism.*  
developmental approach to, 53-67  
developmental measures and, DSM-IV and, 62-65  
diagnosis of, DSM-III-R procedures for, 61-62
- Autohypnotic symptoms, in mental status examination for assessment of MPD and dissociative disorders, 580-586
- Automatic thoughts, MPD and, 663-665
- Autonomic response, monitoring of, in electroconvulsive therapy, 847
- Avoidance, MPD and, 592-593
- Avoidant personality disorder, comorbidity of MPD and, 560-561
- Behavior, form and function of, 56  
longevity, duration, and frequency of, 57-58  
MPD and, 570-571, 573-574
- Behavioral assessment, in child dissociative disorder diagnosis, 636-639  
nongognitive, in Alzheimer's disease, 320-322
- Behavioral pathology in Alzheimer's Disease scale, 321-322
- Behavioral problems, in Alzheimer's disease, 341-349  
agitation, 342-344  
benzodiazepines in management of, 380-381  
neuroleptic drugs in management of, 353-371  
passivity, 345  
prevalence of, 341-342  
psychosis and, 345-346  
sleep disturbance and, 346  
therapeutic approaches to, 347-348, 353-371, 380-381  
wandering, 344-345  
in dementia, benzodiazepines and, 375-383  
management of, child dissociative disorders and, 644-646
- Behavioral states, 524-525
- Behavioral traits, genetic influences on, 125-126
- Benzodiazepines, behavioral symptom management with, in demented patients, 375-383  
and cognitive impairment, 301-302  
in MPD, 735-736  
and seizure threshold, in ECT, 817-819
- Beta-amyloid, and cognitive impairment in Alzheimer's disease, 471
- Beta-blockers, in MPD, 734-735
- Beta-endorphins, in Alzheimer's disease, 429, 430
- Biologic markers, primary degenerative dementia and, 245
- Bipolar disorder, ECT in, prophylactic, 955
- Birth complications, and speech and language disorders, 98-99
- Birth order, and speech and language disorders, 98
- Blackouts, in MPD, 573
- Blessed rating instruments, for dementia assessment, 310-311
- Blood flow, cerebral, ECT and, 877-878  
regional, Alzheimer's disease and, 453-454
- Blood pressure, agents lowering, ECT and, 874
- Body. *See also Physiology.*  
embodied alternative identities and, identification of, 773-774
- Body schema, development of, 152-153
- Borderline personality disorder, comorbidity of MPD and, 556-559  
MPD versus, 544
- Brain, ECT effects on, 877-878  
fluid volume in, Alzheimer's disease and, 445-446
- Brain peptides. *See Neuropeptides.*
- Brain tumor, ECT and, 878-880
- Brief Cognitive Rating Scale, 312-313
- Caffeine, ECT and, 861-863
- Calcium channel blockers, for cognitive impairment in Alzheimer's disease, 471
- Cardiac pacemakers, ECT and, 876
- Cardiovascular system, ECT effects on, 872-873  
risk management, 873-877
- Caregiver. *See also Family entries.*  
Alzheimer's disease and, burden of, 386  
negative impact of, 386-387
- Case management, psychotherapy and, for MPD, 649-659
- Central nervous system, ECT and, risk management, 878-881
- Central nervous system peptides. *See Neuropeptides.*
- CERAD (Consortium to Establish a Registry for Alzheimer's Disease), 225-228
- Cerebral blood flow, ECT and, 877-878
- Cerebral permeability, ECT and, 878
- Cerebral trauma, ECT and, 880-881

- Cerebral vascular malformation, ECT and, 880
- Children, autistic. *See Autism.*
- with autistic features, in Asperger's syndrome, 81-82. *See also Asperger's syndrome.*
- disabled, family and, 199-213
- parental reactions to, 185-192
- dissociative disorders in, 519-529
- developmental substrates of, 520-526
- diagnosis of, 526-528, 632-640
- diagnostic and conceptual issues in, 520
- differential diagnosis of, 639-640
- future study of, 529
- treatment of, 528, 631-647
- normal. *See also Development, normal.*
- development of theory of mind in, 36-37
- psychopathology in, developmental and medical models for, 54-58
- schizotypal personality disorder in, Asperger's syndrome versus, 86
- trauma in. *See Trauma, childhood.*
- Cholecystokinin octapeptide, in Alzheimer's disease, 431
- Choline acetyltransferase, in Alzheimer's disease, 290
- Cholinergic agonists, for cognitive impairment in Alzheimer's disease, 462-464
- Cholinergic system, and Alzheimer's disease, 289-292
- clinical, neurochemical, and neuropathologic correlates of, 291-292
- neurochemical and receptor changes in, 290-291
- pharmacology and, 295-300
- scopolamine and, 295-299, 300
- anatomy of, 289, 290
- neurochemistry of, 289, 291
- Cholinomimetic drugs, for cognitive impairment in Alzheimer's disease, 462-467
- Chromosomes, genetic markers on, Alzheimer's disease and, 279-281
- Clinical Dementia Rating scale, 226, 317
- Clinician, MPD patient's impact on, 571
- Clonidine, in MPD, 734-735
- Cluster A personality disorders, MPD and, 550-553
- Cluster B personality disorders, MPD and, 553-560
- Cluster C personality disorders, MPD and, 560-564
- Coconscious multiple personality disorder, 622
- Cognition-enhancing drugs, in Alzheimer's disease, 469-470
- Cognitive dissonance, establishment of, in MPD, 665-670
- Cognitive function, autism and, 11
- Cognitive impairment, in Alzheimer's disease, treatment of, 461-474
- drugs and, 300-302
- stimulus intensity and, in ECT, 807-808
- Cognitive model, in MPD treatment, 662-674
- Cognitive restructuring, with MPD patients, 663-665
- Cognitive-developmental systems theory in pervasive developmental disorders, 141-161
- correction of developmental dysfunctions and, 149-160
- integration of center and home and, 160-161
- reality systems and, 147-149
- sign stage of development and, 142-147
- Collaborative evaluation, legal evidence and, MPD and, 751
- Communication. *See also Language disorders.*
- development of, developmental dysfunctions and, 156-160
- forensic issues of, MPD and, 752-753
- with outpatient psychotherapist, hospitalized MPD patient and, 710-711
- Community referral, Alzheimer's disease and, family and, 389
- Companionship, imaginary, 523-524
- ostensible, 623
- Compensatory action phase of sign stage of development, 145-147
- Competency, Alzheimer's disease and, 391-392
- to stand trial, MPD and, 742-746
- substitute consent and, for ECT, 1010-1012
- Comprehensive dementia assessments, 310-313, 317
- Compulsive personality disorder, comorbidity of MPD and, 561-562
- Computerized tomography, in Alzheimer's disease, 444-446
- Consent, informed. *See Informed consent.*
- substitute, for ECT, 1010-1012
- Consortium to Establish a Registry for Alzheimer's Disease (CERAD), 225-228
- Contact, synchrony of, autism and, 27
- Continuity of care, MPD and, 649-659
- Cooperation with outpatient psychotherapist, hospitalized MPD patient and, 710-711
- Coping, developmental dysfunctions and, 153-155
- general style of, MPD and, 537-538
- Cornell Scale for Depression in Dementia, 321
- Corticotropin releasing factor, in Alzheimer's disease, 427-429

- Covert multiple personality disorder, 623-625
- Craniotomy, ECT and, 880-881
- Crisis management, in MPD, 657-659
- Crisis prevention, in MPD, 661-674
- Death instinct, identity and development and, in MPD, 683-686
- Décalage, as organizing construct in autism diagnosis, 60-62
- Dementia, assessment of, 310-313
- behavioral symptoms of. *See also Behavioral problems, in Alzheimer's disease.*
- benzodiazepines in management of, 375-383
- neuroleptic drugs in management of, 355-356
- combined lesions causing, 244
- degenerative, primary, 239-240, 245
- depression in, prevalence of, 327-329
- depression-associated, 244-245, 329-330
- differential diagnosis of, neuropathologic findings and, 238-239
- established diagnostic criteria for, need for, 237-238
- multi-infarct, 241-244
- reversible, depression with, 329-330
- senile. *See Alzheimer's disease; Senile dementia.*
- subcortical, and Parkinson's disease, 240-241
- Dementia Behavior Disturbance Scale, 322
- Dementia Mood Assessment Scale, 321
- Dependent personality disorder, comorbidity of MPD and, 562-563
- Depersonalization, MPD and, 584
- Depression, in Alzheimer's disease, 327-336
- assessments of, 320-321
- biologic findings in, 332-334
- clinical findings and family history of, 331-332
- clinical presentation and course of, 330-331
- differential diagnosis of, 334-335
- prevalence of, 327-329
- treatment of, 335-336
- dementia associated with, 244-245
- prevalence of, 327-329
- reversible, 329-330
- ECT resistance and, treatment in, 917-920
- family history of, and Alzheimer's disease, 331-332
- Detachment, MPD and, 592-593
- Development, atypical, 55-56
- delayed, 55-56
- identity and death instinct and, in MPD, 683-686
- normal, 8-10, 21-23
- sign stage of, in cognitive-developmental systems theory, 142-147
- Developmental disorders, effects on family of, 183-195, 199-213
- systems perspective and, 200
- language impairment and, 99-104
- Asperger's syndrome versus, 85
- outcome and, 106-107
- pervasive. *See Pervasive developmental disorders.*
- Developmental level, intraindividual differences in, 59-60
- measures of, 58-60
- DSM-IV and, 62-65
- Deviance, social, in autism, 19-30
- Diagnostic measures, results of, interpretation of, 75-76
- Diazoxide, ECT and, 874-875
- Differential learning, memory and, in MPD patients, 494-495
- Diminished capacity, MPD and, 747
- Direct observation, in diagnostic information collection, autism and, 74-75
- Disabled child, family and, 199-213
- parental reactions to, 185-192
- Dissociation. *See also Dissociative disorders; Multiple personality disorder (MPD).*
- contribution of, to other psychiatric disorders, 498
- epidemiology of, 490-491, 503-515
- history of, in child, 636
- "micro," MPD and, 579-580
- normative, 521-523
- as part of trauma response, 547-550
- psychophysiology of, 491-494
- recent research into, 490-498
- standardized measures of, 506-507
- Dissociative disorders. *See also Dissociation; Multiple personality disorder (MPD).*
- assessment of, symptom cluster method for, 572-602
- childhood trauma and, 505-506
- in children and adolescents, 519-529. *See also Children, dissociative disorders in.*
- chronic complex, office mental status examination for, 567-602
- worldwide prevalence of, 511
- developmental antecedents of, 495-496
- inpatient diagnosis of, in children, 632-640
- prevalence of, 505
- in clinical populations, 507
- in general population, 508-515
- worldwide, 511
- psychological testing correlates of, 496-497

- Dissociative disorders (*Continued*)  
 specialized programs for, in hospitals, 715-717
- Dissociative symptoms, complex, clinical mental status examination for, 568-571
- Dopamine agonists, 115-117
- Down's syndrome, Alzheimer's disease and, 259
- Drugs. *See also* specific drug or type of drug.  
 and cognitive impairment, 300-302  
 effect on seizure threshold, in ECT, 816-819  
 frontal lobe, 115-117  
 interactions, ECT and, 895-896  
 in MPD treatment, 721-738  
   comorbidity and, 729-737  
   in hospital, 714  
   problems not solvable with, 727-729  
   state-dependent effects in, 723-724  
   total treatment context and, 724-727  
 in pervasive developmental disorders, 165-179  
   clinical guidelines for, 176-178  
   fenfluramine, 172-173  
   lithium carbonate, 174  
   magnesium, 174-175  
   methylphenidate, 171-172  
   naltrexone, 173-174  
   neuroleptic drugs, 166-171  
   pyridoxine, 174-175  
   seizures due to, 176  
   selection for treatment, 175-176  
 resistance to, ECT response and, 906-911, 920  
   relapse following ECT and, 911-917, 920-921  
 temporal lobe, 117-118
- DSM-III-R, autistic disorder and, 61-62
- Axis II disorders in, comorbidity of MPD and, 547-565
- MPD criteria in, heterogeneity of individuals meeting, 510-511
- DSM-IV, autistic disorder and, 53-67
- developmental measures and, 62-65
- DuP 996, for cognitive impairment in Alzheimer's disease, 467
- Dyskinesia, tardive, neuroleptic drugs causing, 167-171
- Dyslexia. *See also* Language disorders.  
 familiarity of, 105
- Dysphoria, maternal, parental stress and, effects on marital subsystem of, 206-210
- ECT. *See* Electroconvulsive therapy.
- Ectopy, agents reducing, in ECT, 875
- Educational support, in nursing care, in electroconvulsive therapy, 971-972
- EEG. *See* Electroencephalography.
- Ego functioning, improvement of, child dissociative disorders and, 644-646
- ElCoT, Inc., ECT devices, 1002-1004
- Elective mutism, language impairment and, 100-101
- Electroconvulsive therapy (ECT), 793-1020  
 bilateral, efficacy of, 826, 827  
   for mania, 892-893  
   options for patients unresponsive to, 920  
 cardiovascular effects of, 872-873  
   risk management, 873-877  
 cerebral effects of, 877-878  
   risk management, 878-881  
 clinical response to, speed of, 827-829  
 devices for, battery operation, 1002  
   displays and, 993, 999, 1001, 1003-1004  
   ElCoT, Inc., 1002-1004  
   glissando feature, 1002  
   manufacturers of, 1005  
   MECTA Corporation, 992-998  
   Medcraft Corporation, 1000-1002  
   patient monitoring and, 991-992, 993, 998, 999, 1001-1002, 1004  
   printouts and, 993, 999, 1001, 1004  
   programmable treatment options and, 1004  
   selection of, 989-1005  
   self-testing mechanisms and, 993, 999, 1001, 1003  
   Somatics, Inc., 998-1000  
   starter kit and, 998, 1000, 1002, 1004  
   static impedance and, 993, 999, 1003  
   stimulus energy and, 990-991, 992-993, 996-997, 998, 1000-1001, 1003  
   wave form and, 990  
 dosing in, absolute versus relative, 827  
 drug interactions with, 895-896  
 efficacy of, seizure duration and, 834-836  
   stimulus intensity and, 822-829  
 electrode placement in, seizure threshold and, 810-813  
 inadequate seizures in, management of, 859-863  
 informed consent and, 973, 1009-1010  
   sample form for, 1017-1020  
 legal and ethical issues in, 1007-1020  
 low-dose, titrated, 823-826  
 maintenance, 947-958  
   in mania, 894-895  
   nursing care in, 979-980  
   for mania, 887-899  
 in medically compromised patient, 871-881  
 missed seizures in, detection of, 857-858

- management of, 858-859
- monitoring and management in, 845-866
  - equipment and, 991-992, 999-1000, 1001-1002, 1004
  - mania and, 896
  - neuroendocrine testing in, 961-967
  - nursing care in, 971-988
  - optimal use of, 935-945
  - in Parkinson's disease treatment, 925-931
  - prolonged seizures in, defined, 863-864
    - detection of, 864
    - incidence of, 864
    - management of, 864-865
    - toxicity of, 864
  - prophylactic. *See also Electroconvulsive therapy, maintenance.*
    - in mania, 894-895
  - regulatory issues, 897-898
    - history of, 1008-1009
  - relapse following, medication resistance and, 911-917, 920-921
  - resistance to, depression and, 917-920
  - restimulation in, alternatives to, 860-861
  - revival in United States of, antipsychiatry movement and, 793-800
  - seizure duration in, 829-836
    - efficacy and, 834-836
    - factors related to, 829-834, 857
  - seizure monitoring in, 845-857
    - EEG in, 847-857
    - motor response in, 845-847
  - seizure threshold in, age and, 813-815
    - anesthetic agents and, 815-816
    - diagnostic categories and, 816
    - dosing effects and, 808-810
    - ECT devices and, 805
    - electrode placement and, 810-813
    - factors predicting or influencing, 810-822, 857
    - gender and, 810
    - psychotropic medications and, 816-819
    - range in, 805-807
    - stimulus intensity and, 804-822
  - in special populations, 896-897
  - stimulus intensity in, cognitive deficits and, 807-808
    - efficacy and, 822-829
    - seizure threshold, seizure duration and, 803-838
  - substitute consent and, 1010-1012
  - treatment schedule for, 935-945
    - current clinical practice, 936-937
    - direct comparisons of, 941-944
    - evidence from real versus simulated studies, 938-941
    - implications of, 937-938
  - in treatment-resistant patient, 905-921
    - history of, 905-906
    - medication resistance and response, 906-911, 920
    - relapse, 911-917, 920-921
    - unilateral, efficacy of, 826, 827
      - for mania, 892-893
- Electroencephalography (EEG), in clinical practice monitoring, evolution of, 847-848
  - in ECT, 847-857
  - ictal, interpretation of, 851-857
    - scalp distribution of, 851
    - time course of, 849-851
  - recording method in, 848
  - recording sites in, 848-849
- Electromyography (EMG), in electroconvulsive therapy, 847
- Embodied alternative identities, 769-785
- Emotional disorders, language impairment and, 100
- Emotional support, in nursing care, in electroconvulsive therapy, 971-972
- Engagement phase of sign stage of development, 144-145
- Enthrallment, MPD and, 581
- Environment, child dissociative disorders and, inpatient treatment of, 640-643
  - coping with, developmental dysfunctions and, 153-155
- Epochal multiple personality disorder, 622
- Ethical issues, in electroconvulsive therapy, 1007-1020
- Experience, organization of, MPD and, 538-539, 540-542
- Extrapyramidal effects of neuroleptic drugs, 167-171
- Familiality, of autism, 126-131
  - of language impairment and related disorders, 105-106
- Family. *See also Parents.*
  - handicapped child and, 199-213
  - staff and, 160-161
- Family counseling, in Alzheimer's disease, 385-390
  - strategies for, 387-390
- Family education, Alzheimer's disease and, behavioral problems in, 347-348
- Family history studies. *See also Genetics.*
  - in Alzheimer's disease, cumulative risk and, 269-275
    - depression and, 331-332
- Family stress, models of, 184-185
- Family therapy, Alzheimer's disease and, 390
- Fantasy play, 523-524
- Fantasy proneness, in adults, 524
- Fenfluramine, in pervasive developmental disorders, 172-173
- Financial impact, Alzheimer's disease and, caregiver and, 387

- Flashbacks, MPD and, 589-590  
 Forensic issues. *See also Legal issues.*  
   multiple personality and, 741-755  
     diagnostic evaluation of, 747-750, 762-765  
     diminished capacity, 747  
     evidentiary issues, 750-753  
     iatrogenesis and malingering, 757-766  
     insanity and competency to stand trial, 742-746  
     malingering, 753-755, 757-766  
     mitigation, 747  
 Fractionated abstractions, MPD treatment and, 672-673  
 Fragile X, autism and, 131-133  
 Frontal lobe drugs, 115-117  
 Fugues, MPD and, 574-575  
 Functional Assessment Staging, 320
- Galanin, in Alzheimer's disease, 431-432  
 Genetic disorders, autism and, mechanisms of association of, 135  
 Genetic factors in autism, 125-137  
 Genetic transmission, models of, 126-131  
 Genetics. *See also Family history studies.*  
   of Alzheimer's disease, 258-259, 267-284.  
     *See also Alzheimer's disease, clinical genetic studies of.*  
 Geriatric Depression Scale, 321  
 Geropsychiatric patients, benzodiazepines in, 376-379  
 Global Deterioration Scale, 316  
 Global staging scales, Alzheimer's disease and, 315-318  
 Glucose metabolism, regional, Alzheimer's disease and, 449-450  
 Glutamatergic manipulations, for cognitive impairment in Alzheimer's disease, 470-471  
 Growth hormone, electroconvulsive therapy and, 965-966  
 Guardianship, Alzheimer's disease and, 391-392
- Habits, fluctuations in, MPD and, 576-577  
 Hallucinations, MPD and, 582-583, 596-598  
 Haloperidol, 166-167  
 Handicapped child. *See Disabled child.*  
 Heart rate, ECT effects on, 872  
   agents reducing heart rate and, 875  
 Hematoma, subdural, ECT and, 880  
 Hirano bodies, in Alzheimer's disease, 409  
 Histrionic personality disorder, comorbidity of MPD and, 553-554  
 Home. *See Family.*
- Homicide defendants, forensic evaluation of.  
   *See also Forensic issues.*  
   iatrogenesis and malingering of MPD in, 757-766  
 Hydergine, for cognitive impairment in Alzheimer's disease, 470  
 Hydralazine, ECT and, 875  
 Hyperactivity, language impairment and, 99-100  
 Hyperarousal symptoms, MPD and, 591-592  
 Hyperventilation, ECT and, 861  
 Hypnosis, legal evidence and, MPD and, 751-752  
 Hypothalamic pituitary adrenal axis, electroconvulsive therapy and, 962-964  
 Hypothalamic pituitary thyroid axis, electroconvulsive therapy and, 964-965
- Identity(ies), alternative. *See also Alter personalities.*  
   embodied, 769-785  
   development and death instinct and, in MPD, 683-686  
   identifying, body and, 773-774  
   mistaken, MPD and, 578-579  
 Imagery, intrusive, MPD and, 589-590  
 Imaginary companionship, 523-524  
   ostensible, MPD and, 623  
 Individual therapy, for caregiver, Alzheimer's disease and, 390  
 Informed consent, Alzheimer's disease and, 392-393  
   research in, 393-394  
   for ECT, 973, 1009-1010  
   sample form for, 1017-1020  
 Inpatient treatment, of multiple personality disorder, 695-717  
   in children, 631-647  
   discharge criteria in, 704  
   impact of hospital on patient, 706-707  
   impact of patient on hospital, 704-706, 707-710  
   indications for, 698-701  
   lengths and goals of, 701-704  
   management concerns with, 711  
   outpatient psychotherapist and, 710-711  
   patient participation and, 712  
   special tracks in general programs for, 714-715  
   specialized programs for, 715-717  
   treatment issues arising in, 712-714  
 Insanity defense, MPD and, 742-746  
 Instrumental Activities of Daily Living Scale, 320  
 Integration, in MPD therapy, 670-674, 681-683, 689



- Integrative spheres, in correction of developmental dysfunctions, 151
- Intention, development of, during sign stage of development, 145-147
- Interactive studies, autism and, 27
- Interdisciplinary collaboration, nurse in, electroconvulsive therapy and, 980-981
- Interference phenomena, multiple personality disorder and, 594-596
- Intimacy, marital, parenting stress and psychological health and, 209-210
- Intracranial pressure, brain tumor and, ECT and, 879
- Intrusive imagery, MPD and, 589-590
- IQ, and speech and language disorders, 97-98
- Isomorphic multiple personality disorder, 622
- Katz Activities of Daily Living Scale, 319
- Ketamine, ECT and, 863
- Knowledge, fluctuations in, MPD and, 576-577
- Labetalol, ECT and, 876
- Language, Alzheimer's disease and, scopolamine and, 298-299
- Language disorders. *See also Communication.*  
autism and, 11, 23-25, 102-104  
correlates of, 97-99  
developmental disorders and, 99-104  
Asperger's syndrome versus, 85  
outcome and, 106-107  
elective mutism and, 100-101  
emotional disorders and, 100  
epidemiology of, 96-97  
familiarity of, 105-106  
hyperactivity and, 99-100  
learning disabilities and, 101-102
- Learning, differential, in MPD patients, 494-495
- Legal issues. *See also Forensic issues.*  
in Alzheimer's disease, 391-394  
in electroconvulsive therapy, **1007-1020**  
future directions of, 1014-1015  
history of regulation, 1008-1009  
informed consent, 1009-1010  
sample form for, 1017-1020  
malpractice, 1012-1013  
right to effective treatment, 1013-1014  
substitute consent, 1010-1012
- Leisure activities, of caregiver, Alzheimer's disease and, 387
- Lesions, combined, dementia due to, 244
- Lidocaine, ECT and, 875-876
- Life history, fragmentary recall of, MPD and, 577-578
- Linguistic dysfunction. *See also Language disorders.*  
continuum of, **95-107**
- Linguistic usage, MPD and, 598
- Linkage studies, of Alzheimer's disease, 276-282
- Lithium carbonate, in pervasive developmental disorders, 174
- Living will, Alzheimer's disease and, 392
- Logic, trance, MPD and, 584-585
- Magnesium, in pervasive developmental disorders, 174-175
- Magnetic resonance imaging, in Alzheimer's disease, 446-449
- Malingering, MPD and, 753-755, **757-766**
- Malpractice, electroconvulsive therapy and, 1012-1013
- Mania, electroconvulsive therapy for, **887-899**  
case vignettes of, 890-892  
double-blind trials of, 890  
historical background of, 887-890  
maintenance and prophylactic, 894-895  
mechanism of action of, 898-899  
number and frequency of treatments in, 893-894  
regulatory issues, 897-898  
side effects and complications of, 895-897  
technique of, 892-894
- Marital relationship, effects of parental stress and maternal dysphoria on, developmentally handicapped child and, 206-210
- Marital status, parental, and speech and language disorders, 99
- Maternal dysphoria, parental stress and, effects on marital subsystem of, 206-210
- Mattis Dementia Rating scale, 312
- MECTA Corporation devices, for ECT, 992-998
- Medcraft Corporation, ECT devices, 1000-1002
- Medical illness, electroconvulsive therapy in, **871-881**
- Medication. *See Drugs;* specific drug or type of drug.
- Mediumistic multiple personality disorder, 623
- Memory. *See also Amnesia symptoms.*  
Alzheimer's disease and, scopolamine and, 297-298  
differential learning and, in MPD patients, 494-495

- Memory Assessment Clinics Test Battery, 314
- Mental health, of caregiver, Alzheimer's disease and, 387
- Mental retardation, Asperger's syndrome versus, 85
- Mental states, understanding of, autism and, 35-36
- Mental status examination, office, for complex chronic dissociative symptoms and MPD, 567-602
- Methylphenidate, in pervasive developmental disorders, 171-172
- "Micro" dissociations, MPD and, 579-580
- Mind, theory of, in autism, 33-48
- in normal children, 36-37
- Mind deficit, theory of, social cognition and social behavior and, 34-35
- Mini-Mental State Examination, 311-312
- Minispheres, in correction of developmental dysfunctions, 150-151
- Minority populations, and caregiving, in Alzheimer's disease, 390
- Mistaken identity, chronic experiences of, MPD and, 578-579
- Modular multiple personality disorder, 625-626
- Monoaminergic drugs, for cognitive impairment in Alzheimer's disease, 467-468
- Monoamines, in Alzheimer's disease, 423-424
- Mood-stabilizing agents, in MPD, 734
- Morbidity, ontogeny plus, 54-55
- Multi-infarct dementia, 241-244
- Multiple personality disorder (MPD), 489-791. *See also* *Dissociation; Dissociative disorders.*
- ad hoc, 625
- affective symptoms in, 601-602, 730-731
- amnesia symptoms in, 572-580
- anxiety in, 590-591, 732-736
- appearance of patient with, 570
- atypical, 623
- autohypnotic symptoms in, 580-586
- behaviors in, 570-571
- children with. *See also* *Children, dissociative disorders in.*
- inpatient treatment of, 631-647
- classic, 621
- clinical case management of, 650
- psychotherapy synthesis with, 650-651
- clinical phenomenology of, 497-498
- clinical presentations of, 605-627
- coconscious, 622
- comorbidity in, DSM-III-R Axis II disorders and, 547-565
- hospitalized patient and, 717
- psychopharmacology and, 729-737
- covert, 623-625
- crisis management in, 657-659
- crisis prevention in, 661-674
- developmental antecedents of, 495-496
- developmental substrates of, 520-526
- diagnosis of, concerns involving, 608-609
- in forensic setting, 747-750, 762-765
- history of, 606-608
- differential learning and memory in, 494-495
- DSM-III-R criteria for, heterogeneity of individuals meeting, 510-511
- epidemiology of, 490-491, 503-515
- epochal, 622
- extremely complex, 622
- forensic issues in, 741-755
- general coping style in, 537-538
- hospital treatment of, 695-717
- iatrogenesis model of, 511
- identity, development, and death instinct in, 683-686
- inherent instability and vulnerability in, 697-698
- inner structure of, relationship to manifest appearance, 609-616
- isomorphic, 622
- longitudinal presentation of, 616-620
- modular, 625-626
- nature of, 609-610
- office mental status examination for, 567-602
- organization of experience in, 538-539
- traumatic, 540-542
- orphan symptom, 625
- ostensible imaginary companionship, 623
- panic in, 590-591, 732-736
- passive-influence dominated, 594-596, 624
- phenocopy, 624-625
- polyfragmented, 622
- possessioniform, 622-623
- posttraumatic phenomena and, 539-540, 621-622
- posttraumatic stress symptoms in, 586-593
- psychopharmacologic treatment of, 732-736
- private, 623
- process symptoms in, 593-600
- pseudo-false positive, 626
- pseudoseizures in, 731-732
- psychoanalytic perspective of, 677-689
- psychological organization of, 533-545
- psychological testing correlates of, 496-497
- psychophysiology of, 491-494
- psychotherapy and case management for, 649-659
- psychotic-like symptoms in, 729-730
- puppetering, 624
- quasi-roleplaying, 626

- recent research on, 489-500  
 reincarnation/mediumistic, 623  
 Schneiderian symptoms and, 514  
 secret, 623  
 self-destructiveness in, 656-657, 737  
 sequential, 622  
 sleep problems in, 590, 736-737  
 somatoform symptoms in, 600-601, 625, 731-732  
 switch-dominated, 625  
 transitional phenomena in, 680-681  
 treatment of, 498  
   case examples of, 653-654  
   cognitive model in, 662-674  
   creative options in, 654-655  
   dilution phase in, 671-674  
   framework for, 656-657  
   hospital, 695-717  
   integration in, 670-674, 681-683, 689  
   psychoanalytic, 677-689  
   psychopharmacologic, 721-738  
   psychotherapy and case management in, 649-659  
   stabilization of, 661-674  
   stages in, 699-701  
   suppression phase in, 670-671  
   working-through phase in, 686-689  
   variant forms of, 621-623  
 Multispheres, in correction of developmental dysfunctions, 151-152  
 Mutism, elective, language impairment and, 100-101  
 Myocardial infarction, ECT and, 877
- Naltrexone, in pervasive developmental disorders, 173-174  
 Narcissistic personality disorder, comorbidity of MPD and, 555-556  
 Negative hallucinations, MPD and, 582-583  
 Neuroanatomy, functional, of psychiatric treatments, 113-122  
 Neurobiopsychosocial model, 113  
 Neurochemistry, Alzheimer's disease and, 290-292  
 Neuroendocrine testing, in electroconvulsive therapy, 961-967  
   growth hormone, 966  
   hypothalamic pituitary adrenal axis, 962-964  
   hypothalamic pituitary thyroid axis, 964-965  
   neurophysins, 966-967  
   prolactin, 965-966  
 Neurofibrillary tangles, in Alzheimer's disease, 406-409  
 Neuroimaging, in Alzheimer's disease, 443-455
- Neuroleptic drugs. *See also* Drugs; specific drug.  
 adverse effects of, 167-171  
 for behavioral symptoms of Alzheimer's disease, 353-371  
 efficacy of, 358-369  
 toxicity of, 356-357, 368-371  
 in pervasive developmental disorders, 166-171
- Neurons, granulovacuolar degeneration of, in Alzheimer's disease, 409
- Neuropathology, cholinergic system and, Alzheimer's disease and, 291-292  
 and differential diagnosis of dementia, 238-239  
 and learned adaptations, 56-57
- Neuropeptide Y, in Alzheimer's disease, 426-427
- Neuropeptides, in Alzheimer's disease, 424-432  
 drugs affecting, for cognitive impairment in Alzheimer's disease, 468-469
- Neurophysins, electroconvulsive therapy and, 966-967
- Neuropsychologic tests, in Alzheimer's disease assessment, 313-315
- Neurotensin, in Alzheimer's disease, 431
- Neurotransmitter systems, and Alzheimer's disease, 288-300, 409-410, 422-424  
 amino acid neurotransmitters, 432-433  
 cholinergic system, 289-292  
 pharmacologic approaches and, 292-300
- Neurotrophic factors, and cognitive impairment in Alzheimer's disease, 471
- New York University Test Battery, 314
- Nifedipine, ECT and, 875
- Nightmares, MPD and, 590
- Nitrates, ECT and, 874
- Nootropics, for cognitive impairment in Alzheimer's disease, 469-470
- Normal children, development of theory of mind in, 36-37
- Normal development, 21-23  
 theory of, 8-10
- Normative dissociation, 521-523
- Numbing, MPD and, 592-593
- Nursing care, in electroconvulsive therapy, 971-988  
 areas for future research, 982-983  
 educational and emotional support, 971-972  
 informed consent and, 973  
 interdisciplinary collaboration and, 980-981  
 maintenance, 979-980  
 posttreatment, 976-979  
 pretreatment, 973-975  
 during procedure, 975-976  
 staff education and development for, 981-982

- Nursing care (*Continued*)  
standards of care, 985-988
- Observation, in diagnostic information collection, autism and, 74-75
- Obsessive-compulsive disorder, Asperger's syndrome versus, 85-86
- Ontogeny, "atypical," 54-55
- Orienting phase of sign stage of development, 143-144
- Orphan symptom multiple personality disorder, 625
- Ostensible imaginary companionship  
multiple personality disorder, 623
- Out-of-body experiences, MPD and, 584
- Overtiness, aspects of, in MPD, 612-616
- Oxytocin, in Alzheimer's disease, 429, 430
- Pacemakers, ECT and, 876
- Paired helical filaments, in Alzheimer's disease, 406-409
- Panic, MPD and, 590-591, 732-736
- Paranoid personality disorder, comorbidity of MPD and, 550-551
- Parents. *See also Family.*  
age of, and Alzheimer's disease risk, 259  
effects of developmental disorders on, 183-195, 200-206  
interviews with, in diagnostic information collection, autism and, 73-74  
marital status of, and speech and language disorders, 99  
psychiatric illness in, and speech and language disorders, 99  
stress in, developmentally handicapped child and, 200-204, 205  
effects on marital subsystem of, 206-210  
sources of, 204, 206
- Parkinson's disease, Alzheimer's disease and, 259  
subcortical dementia and, 240-241  
treatment of, ECT in, 925-931  
neurobiologic basis of, 930  
recommendations for, 930-931
- Passive-aggressive personality disorder, comorbidity of MPD and, 563-564
- Passive-influence symptoms, multiple personality disorder and, 594-596, 624
- Passivity, in Alzheimer's disease, 345
- Pedigree studies, of Alzheimer's disease, 276
- Peptides. *See Neuropeptides.*
- Personality disorders, MPD and, 550-564
- Personality mapping, in MPD, 670-671
- Personality system, in MPD, 611-612. *See also Alter personalities; Multiple personality disorder (MPD).*
- Pervasive developmental disorders, 1-222  
Asperger's syndrome, 81-91, 129  
autism. *See Autism.*  
cognitive-developmental systems theory in, 141-161  
effects on family of, 183-195, 199-213  
and functional neuroanatomy of psychiatric treatments, 113-122  
linguistic dysfunction and, 93-107  
use of medication in, 165-179. *See also Drugs.*
- Pharmacologic models of Alzheimer's disease, 287-303  
animal studies, 293-295  
human studies, 295-299
- Phenocopy multiple personality disorder, 624-625
- Phenotype definition, and genetic transmission of autism, 128-130
- Phobias, in MPD, 732-736
- Physical Self-Maintenance Scale, 319-320
- Physical wellbeing, of caregiver, Alzheimer's disease and, 386-387
- Physiology. *See also Body.*  
of multiple personality disorder, 491-494
- Play, fantasy, 523-524
- Polyfragmented multiple personality disorder, 622
- Positron emission tomography, in Alzheimer's disease, 449-452
- Possessioniform multiple personality disorder, 622-623
- Possessions, unexplained, MPD and, 575
- Posttraumatic stress symptoms. *See also Trauma.*  
in MPD, 539-540, 586-593, 621-622  
psychopharmacologic treatment of, 732-736
- Pregnancy, complications of, and speech and language disorders, 98-99
- Primary degenerative dementia, 239-240  
biologic markers of, need for, 245
- Private multiple personality disorder, 623
- Process symptoms, in mental status examination for assessment of MPD and dissociative disorders, 580-586
- Prolactin, electroconvulsive therapy and, 965-966
- Pseudo-false positive multiple personality disorder, 626
- Pseudohallucinations, in MPD, 596-598
- Pseudoseizures, in MPD, 731-732
- Psychiatric disorders, childhood trauma in, rates of, 512-514  
contribution of dissociation to, 498  
parental, and speech and language disorders, 99

- prevalence of, 504-505
- Psychiatric treatments, functional neuroanatomy of, 113-122
- Psychoanalytic perspective of multiple personality disorder, 677-689
- Psychogenic amnesia, MPD and, 572-580
- Psychological health, parenting stress and, marital intimacy and, 209-210
- Psychological testing, in MPD and dissociative disorders, 496-497
- psychological organization of patients as revealed in, 533-545
- Psychological trauma. *See also Posttraumatic stress symptoms; Trauma.*
- MPD and, 586-589
- Psychomotor speed ability, Alzheimer's disease and, scopolamine and, 299
- Psychopathology, in children, developmental and medical models for, 54-58
- Psychopharmacology. *See Drugs.*
- Psychophysiology, of MPD and dissociation, 491-494
- Psychosis, in Alzheimer's disease, 345-346
- Psychotherapy, case management and, for MPD, 649-659
- Psychotic-like symptoms, in MPD, 729-730
- Puppetering multiple personality disorder, 624
- Pyridoxine, in pervasive developmental disorders, 174-175
- Quasi-roleplaying multiple personality disorder, 626
- Questionnaires, in diagnostic information collection, autism and, 74
- Reactivity, MPD and, 590-591
- Reality systems, 142
- evaluation of, Umwelt Assessment in, 147-149
- formation and dynamics of, during sign stage of development, 143-145
- Referrals, Alzheimer's disease and, family and, 389
- Reincarnation/mediumistic multiple personality disorder, 623
- Relationships, inexplicable changes in, MPD and, 576
- Representation, development of, developmental dysfunctions and, 156-160
- Research, on multiple personality disorder, 489-500
- strategies for, autism and, 3-5
- Revivifications, MPD and, 589-590
- Ritual embodiment, 780-785
- Schizoid personality disorder, comorbidity of MPD and, 551-552
- Schizotypal personality disorder, Asperger's syndrome versus, 86
- comorbidity of MPD and, 552-553
- Scopolamine, and Alzheimer's disease, 295-299, 300
- animal studies, 294
- Secret multiple personality disorder, 623
- Sedative-hypnotics, in MPD, 735-736
- Seizures, electrically induced. *See Electroconvulsive therapy (ECT).*
- neuroleptic drugs causing, 176
- Self-destructiveness, in MPD, 656-657, 737
- Senile dementia. *See also Alzheimer's disease.*
- mild, 232-233
- very mild, 230-232
- Sequential multiple personality disorder, 622
- Services referral, Alzheimer's disease and, family and, 389
- Sex differences, and autism, 127, 128
- and seizure threshold, in ECT, 810
- Siblings, of developmentally handicapped child, 210-213
- Sign stage of development, in cognitive-developmental systems theory, 142-147
- development of intention during, 145-147
- formation and dynamics of reality systems during, 143-145
- Single photon emission computed tomography, in Alzheimer's disease, 452-454
- Skills, fluctuations in, MPD and, 576-577
- SKT Test battery, 314
- Sleep, disturbance of, in Alzheimer's disease, 346
- in MPD, 590, 736-737
- Social activities, of caregiver, Alzheimer's disease and, 387
- Social behavior, social cognition and, theory of mind deficit and, 34-35
- Social contact, development of, developmental dysfunctions and, 155-156
- Social deviance, in autism, 11, 19-30
- Social impairments, Wing's triad of, 61
- Socioeconomic status, and speech and language disorders, 97
- Somatics, Inc., ECT devices, 998-1000
- Scotomiform symptoms, in MPD, 600-601, 625, 731-732
- Somatostatin, in Alzheimer's disease, 424-427

- Spectroscopy, magnetic resonance imaging, in Alzheimer's disease, 449
- Speech disorders. *See also Language disorders.*  
correlates of, 97-99
- Spheres, in correction of developmental dysfunctions, 149-152
- Staff, education and development, for nursing care in ECT, 981-982
- family and, 160-161
- MPD patient's effect on, 704-706
- coping with, 707-710
- pediatric, 646
- Standards of care, nursing, for patient receiving ECT, 985-988
- Stress, family, models of, 184-185
- parenting, developmentally handicapped child and, 200-204, 205
- effects on marital subsystem of, 206-210
- sources of, 204, 206
- posttraumatic. *See Posttraumatic stress symptoms.*
- MPD and symptoms of, 586-593
- Stroke, ECT and, 880-881
- Subcortical dementia, and Parkinson's disease, 240-241
- Subdural hematoma, ECT and, 880
- Substance P, in Alzheimer's disease, 430-431
- Substitute consent, for electroconvulsive therapy, 1010-1012
- Support, in nursing care, in electroconvulsive therapy, 971-972
- Support groups, Alzheimer's disease, 390
- Surgery, cardiac, ECT and, 877
- Surroundings, coping with, developmental dysfunctions and, 153-155
- Switch-dominated multiple personality disorder, 625
- Switching, in MPD, 598-600
- Sympathoadrenal cardiovascular effects, prevention of, ECT and, 874-876
- Symptom cluster method, for assessment of MPD and dissociative disorders, 572-602
- affective symptoms in, 601-602
- amnesia symptoms in, 572-580
- autohypnotic symptoms in, 580-586
- posttraumatic stress symptoms in, 586-593
- process symptoms in, 593-600
- somatiform symptoms in, 600-601
- Synchrony of contact, autism and, 27
- Systems perspective, on effects of developmental handicap, 200
- Tardive dyskinesia, neuroleptic drugs causing, 167-171
- Temporal lobe drugs, 117-118
- Tetrahydrocannabinol (THC), and cholinergic function, 299
- Theory of mind hypothesis. *See also Mind, theory of.*  
autism and, 33-34
- Therapeutic alliance, child dissociative disorders and, 643-644
- Thioridazine, 176
- and cholinergic function, 299-300
- Thought disorder, dissociative, 584-585
- Thymatron, 998-1000
- Thyroid disease, Alzheimer's disease and, 259, 261
- Thyrotropin releasing hormone, in Alzheimer's disease, 431-432
- Time loss, MPD and, 573
- Time sense, in children, 525
- Trance logic, MPD and, 584-585
- Trances, spontaneous, MPD and, 580-581
- Trauma. *See also Posttraumatic stress symptoms.*  
cerebral, ECT and, 880-881
- childhood, developmental substrates of multiple personality disorder and, 525-526
- dissociative disorders and, 505-506
- psychiatric disorders and, 512-514
- psychological, MPD and, 586-589
- Trauma response, dissociation as part of, 547-550
- Traumatic experience, organization of, MPD and, 540-542
- Traumatic reenactment, MPD and, 657-658
- Treatment-resistant patient, electroconvulsive therapy in, 905-921
- Tricyclic antidepressants. *See Antidepressants, tricyclic.*
- Trifluoperazine, 167
- Trimethaphan, ECT and, 874
- Tuberous sclerosis, autism and, 133-135
- Tumor, brain, ECT and, 878-880
- Twin studies, of Alzheimer's disease, 268-269
- Umwelt Assessment, 147-149
- Vagal cardiovascular effects, prevention of, ECT and, 873-874
- Vascular disease, dementia due to, Alzheimer's disease and, 411
- Vasoactive intestinal peptide, in Alzheimer's disease, 431
- Vasopressin, in Alzheimer's disease, 429-430

- Videotaping, legal evidence and, MPD and, 750
- Visuospatial ability, Alzheimer's disease and, scopolamine and, 299
- Vitamin B<sub>6</sub>, in pervasive developmental disorders, 174-175
- Voluntary anesthesia/analgesia, MPD and, 583-584
- Wandering behavior, in Alzheimer's disease, 344-345
- White matter, Alzheimer's disease and, 446-447
- Wing's triad of social impairments, 61
- Withdrawal emergent syndrome, 169-170